Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

AI decision support system non-homogenously influences clinical decisions in dynamic treatment regimen, as it depends on several factors including prior knowledge, preference, disease type ...

DelveInsight’s Merkel Cell Carcinoma Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

Discover why Exact Sciences, a leading oncology diagnostics company, may see growth in the cancer diagnostics market with its ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

DelveInsight's Merkel Cell Carcinoma Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 30, 2025 /EINPresswire ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...